METHOD OF TREATING INFECTIOUS DISEASE, METHOD OF PREVENTING PUTREFACTION OF COSMETIC, AND ANTIBACTERIAL/ANTIFUNGAL AGENT AND COSMETIC
申请人:OTSUKA PHARMACEUTICAL CO., LTD.
公开号:EP0589047A1
公开(公告)日:1994-03-30
A method of treating infectious diseases caused by bacteria or fungi by administering a zinc compound and at least one compound selected from the group consisting of hinokitiol and salts thereof; a method of preventing putrefaction of cosmetics by adding thereto a zinc compound and at least one compound selected from the group consisting of hinokitiol and salts thereof; and antibacterial/antifungal agents and cosmetics each containing a zinc compound and at least one compound selected from the goup consisting of hinokitiol and salts thereof.
Reaction products of polyfunctional compounds with two or more coordination elements are described.
描述了具有两个或更多配位元素的多官能团化合物的反应产物。
Compositions, kits and regimens for the treatment of skin, especially décolletage
申请人:Jr Chem, LLC
公开号:EP2087880A2
公开(公告)日:2009-08-12
Compositions, kits and regimens for treatment of damaged skin, especially décolletage, include application of a retinoid, hydroquinone or hydroquinone derivatives, and a composition containing a multi-metal complex.
The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate, alone or optionally, in combinations with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar H+-ATPase or H+/K+-ATPase) and upper body region of the stomach (by inhibiting H+/K+-ATPase), thus raising the pH of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase. This method is also directed to treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.